Deutsche Bank raised the firm’s price target on AbbVie (ABBV) to $180 from $175 and keeps a Hold rating on the shares. The company reported a quality Q3, but Emraclidine success looks already priced in, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: